Tumor lysis syndrome cost-effectiveness of therapy

Tumor lysis syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Tumor lysis syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Tumor lysis syndrome cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Tumor lysis syndrome cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Tumor lysis syndrome cost-effectiveness of therapy
CDC on Tumor lysis syndrome cost-effectiveness of therapy
Tumor lysis syndrome cost-effectiveness of therapy in the news
Blogs on Tumor lysis syndrome cost-effectiveness of therapy
Directions to Hospitals Treating Tumor lysis syndrome
Risk calculators and risk factors for Tumor lysis syndrome cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.

Cost-Effectiveness of Therapy

In patients with malignancies, the cost-effectiveness of administration of a singe low dose (3 mg) of rasburicase for tumor lysis syndrome prevention may be superior to the daily intravenous allopurinol.